Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Shoulder Innovations, Inc. SI

Healthcare — Medical Devices
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.21
Total sells
5.47
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — 2 — — 3 — — — — — —
Sell — — — — — — — — 1 1 5 1
Insider Ownership
44.59%

Capital & Financial Ratios

Market Cap
370.58
Revenue
60.06
Net Income
(35.03)
Free Cash Flow
(47.08)
Net Debt
(84.18)
Current Ratio
10.71
Debt/Equity
0.12
P/E ratio
0.00
P/S ratio
6.27
P/B ratio
3.03
Past 5Y EPS Growth
—
This Y EPS Growth
59.60%
Next Y EPS Growth
16.43%
Next 5Y EPS Growth
32.53%
in millions of $

Dividends

Payout Ratio
—
Annual Dividend Rate
—
Annual Dividend Yield
—

Assets vs Liabilities

2023 2024 2025 Q'26
Cash — 15.04 124.31 98.99
Receivables — 5.12 8.27 10.87
Inventory — 13.96 21.59 22.92
Other — 0.57 1.48 2.29
— 35.13 157.17 137.41
2023 2024 2025 Q'26
Payables — 4.86 8.87 5.93
ST’ Debt — — — —
Other — — — —
— 7.65 14.20 12.83
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Revenue

Mar Jun Sep Dec Year
’26 16.71 17.18 — —
—
’25 10.13 11.01 11.76 14.42
47.32
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (12.36) (7.39) — —
—
’25 (6.48) (4.80) (8.55) (8.78)
(28.61)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (15.09) (9.55) — —
—
’25 (7.32) (6.26) (11.37) (11.06)
(36.02)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.41) (0.49) — —
—
’25 (52.13) (165.53) (0.64) (0.38)
(4.65)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — — — — — — 10.92 — — —
Low Price
— — — — — — — — — 17.94 — — —
High Price
— — — — — — — — 61 75 — — —
Employees
— — — — — — — — 0.52 0.63 — — —
Revenue/Emp
— — — — — — — — 31.62 47.32 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — — — — — — — 76.97% 76.51% — — —
Gross Margin
— — — — — — — — (15.62) (40.36) — — —
EBT
— — — — — — — — (49.39%) (85.29%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— — — — — — — — (15.62) (40.36) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — — — — — — — 2.50 3.46 — — —
Depreciation
— — — — — — — — 490.28 5.46 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — — — — — — — (242.04) (4.65) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — — — — — — — (219.27) (3.30) — — —
Cash Flow/Sh
— — — — — — — — (62.25) (0.85) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — — — — — — — (281.52) (4.15) — — —
Free CF/Sh
— — — — — — — — 306.67 16.23 — — —
Book Value/Sh
— — — — — — — — 0.06 8.67 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — — — 0.00 0.00 ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — — — — — — — 0.05 2.62 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — — — 0.00 0.88 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — — — (0.63) 0.31 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — — — — — — — 0.98 (0.41) — — —
EV/FCF
— — — — — — — — (14.14) (28.61) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — — — — — — — (4.01) (7.41) — — —
Capex
— — — — — — — — (18.16) (36.02) — — —
FCF
— — — — — — — — 27.48 142.97 — — —
Working Cap'
— — — — — — — — 14.66 14.91 — — —
Total Debt
— — — — — — — — (0.39) (109.39) — — —
Net Debt
— — — — — — — — 19.78 140.75 — — —
Sh' Equity
— — — — — — — — 0.00% (37.90%) — — —
ROA
— — — — — — — — (47.22%) (52.42%) — — —
ROIC
— — — — — — — — 0.00% (93.80%) — — —
ROE
predictions in italic, sparklines do not include predictions

Shoulder Innovations, Inc. (SI) Latest News

News by impact score

Fine-tune

10 Sep

4 , 4:05 PM
Shoulder Innovations received FDA 510(k) clearance for N-22 Humeral Head and initiated full commercial launch. FDA clearance and commercial launch of core product directly expands revenue opportunities and market reach.

9 Sep

4 , 4:05 PM
Shoulder Innovations, Inc. enters exclusive partnership with ALM Ortho to launch bespoke solution for complex shoulder reconstruction procedures. Exclusive partnership introduces bespoke solutions that strengthen SI's competitive position in shoulder reconstruction.

4 , 7:00 AM
Shoulder Innovations, Inc. (SI) reported its financial results for the second quarter of 2025, highlighting significant revenue growth and advancements in product development. The company attributed its success to increased demand for its shoulder implant solutions and strategic partnerships. SI's management expressed optimism about future market opportunities and ongoing innovation efforts, which are expected to enhance its competitive position in the orthopedic sector. Significant revenue growth and advancements in product development indicate a strong potential for future market performance.

8 Sep

3 , 4:05 PM
Shoulder Innovations, Inc. settles patent litigation with Catalyst OrthoScience. Settlement ends patent dispute and associated legal costs while preserving operational focus.

9 Aug

3 www.marketbeat.com, 2:03 AM
Shoulder Innovations held its Q2 earnings call and released associated highlights covering financial results and operations. Q2 earnings highlights deliver updates on performance that can moderately affect near-term investor sentiment.

7 Aug

4 transcript , 1:06 AM
Shoulder Innovations Inc (SI) reported Q2 2026 earnings with revenue surging 56%. 56% revenue surge in Q2 2026 drives major gains in financial performance and investor outlook for Shoulder Innovations Inc.

6 Aug

4 , 4:05 PM
Shoulder Innovations, Inc. reported second quarter 2026 financial results and raised its full year outlook. Raising full year outlook signals strong results and improved future prospects.

3 , 7:10 PM
Shoulder Innovations, Inc. reported a Q2 loss while exceeding revenue estimates. Q2 loss with revenue beat signals mixed results likely to produce moderate short-term effects on performance and sentiment.

29 Jun

4 , 7:00 AM
Shoulder Innovations closes credit facility of up to $50 million. Up to $50 million credit facility delivers major capital access that can shift operations and growth trajectory.

16 May

3 Simply Wall St., 9:59 AM
Shoulder Innovations, Inc. released first-quarter earnings. Analysts assess the results and provide views on company performance. Quarterly earnings data and analyst commentary typically drive moderate short-term shifts in valuation and sentiment.

15 May

4 www.marketbeat.com, 4:09 AM
Shoulder Innovations, Inc. (SI) released Q1 earnings call highlights detailing financial performance, operational updates, and forward guidance. Q1 earnings call highlights cover financial results and strategic outlook, likely driving significant shifts in investor sentiment and company trajectory.

14 May

3 app.moby.co, 8:30 AM
Shoulder Innovations, Inc. released Q1 2026 earnings results and outlook during its earnings call. Quarterly earnings provide financial updates that may affect short-term sentiment but rarely shift long-term trajectory.

13 May

4 transcript Benzinga, 5:32 PM
Shoulder Innovations, Inc. (SI) released Q1 2026 earnings call transcript detailing first-quarter financial results, operational updates, management discussion, and forward-looking guidance. Q1 earnings results, guidance, and strategic updates directly impact financial performance, investor sentiment, and market trajectory.

4 PR Newswire, 4:05 PM
Shoulder Innovations, Inc. (SI) reported first quarter 2026 financial results and raised its full-year outlook. Raising full-year outlook after Q1 results signals strong financial health and boosts investor sentiment significantly.

3 Zacks, 5:35 PM
Shoulder Innovations, Inc. (SI) reported a Q1 net loss but exceeded revenue estimates. Q1 revenue beat despite loss moderately influences financial performance and investor sentiment without major trajectory shift.

27 Apr

4 PR Newswire, 7:00 AM
Shoulder Innovations, Inc. initiates full commercial launch of the InSet™ I-135RFX Humeral Stem, a stemmed shoulder system implant designed for primary and revision total shoulder arthroplasty. Full commercial launch of a new humeral stem marks a major product rollout enhancing revenue potential and competitive positioning in shoulder arthroplasty.

10 Mar

4 www.marketbeat.com, 6:41 PM
Shoulder Innovations reported strong Q4 results in earnings call highlights, with revenue up 25% year-over-year to $12.5 million driven by Inset stemless shoulder system. Full-year 2023 revenue hit $42 million, exceeding guidance. Company raised 2024 outlook to $55-60 million, announced European expansion and new product launches. Management highlighted competitive edge in shoulder arthroplasty market. Robust Q4 revenue growth, raised 2024 guidance, and strategic expansions position Shoulder Innovations for significant trajectory improvement.

3 PR Newswire, 4:05 PM
Shoulder Innovations, Inc. (SI) reported fourth quarter and full year 2025 financial results. Q4 and full year financial results directly affect financial performance and investor sentiment.

5 Feb

3 Investing.com, 3:28 AM
Pandora plans to shift its focus to platinum jewelry due to ongoing challenges in the silver market, which has affected its production and pricing strategies. The company aims to enhance its product offerings and cater to changing consumer preferences, potentially boosting its market position amid fluctuating metal prices. The shift to platinum may moderately influence Pandora's financial performance and competitive positioning in the jewelry market.

31 Jan

4 Simply Wall St., 7:42 AM
Shoulder Innovations, Inc. (SI) has attracted significant interest from institutional investors, holding a 38% stake in the company. This level of investment indicates confidence in SI's potential for growth and market performance, suggesting that institutional players see value in the company's operations and future prospects. Institutional investment at this level typically signals strong confidence in the company's strategic direction and growth potential.

30 Dec

3 www.insidertrades.com, 4:39 PM
In 2025, insiders at Shoulder Innovations, Inc. (SI) made significant stock purchases, indicating strong confidence in the company's future. The article highlights the top five stocks bought by these insiders, showcasing their strategic investments and potential implications for market performance. Such insider activity often reflects positive sentiment about the company's prospects and may influence investor perceptions. Insider buying suggests confidence in the company's future, which may moderately influence market sentiment and performance.

3 Dec

4 PR NewswireZacksMedTech DiveMedTech DiveZacksZacksBarchartZacks, 7:00 AM
Shoulder Innovations, Inc. (SI) has announced a strategic partnership with INS to develop a robotic platform aimed at enhancing shoulder arthroplasty procedures. This collaboration is expected to leverage advanced technology to improve surgical outcomes and patient recovery times, positioning SI at the forefront of innovation in orthopedic surgery. The partnership with INS to introduce a robotic platform is a significant strategic move that could enhance SI's competitive positioning and market presence in orthopedic surgery.

12 Nov

4 www.fool.com, 2:35 PM
Shoulder Innovations, Inc. (SI) stock surged significantly today following the announcement of a groundbreaking new shoulder implant technology that promises to enhance patient recovery times and improve surgical outcomes. The innovative product has garnered attention from healthcare professionals and investors alike, leading to increased trading volume and positive market sentiment. Analysts predict that this development could position SI as a leader in the orthopedic market, potentially driving future revenue growth and expanding its market share. The introduction of a groundbreaking shoulder implant technology is likely to significantly impact the company's future performance and market positioning.

11 Nov

4 PR Newswire, 4:05 PM
Shoulder Innovations, Inc. (SI) reported its financial results for the third quarter of 2025, showcasing strong performance and an increase in full-year revenue guidance. The company highlighted growth in key product lines and improved operational efficiencies, contributing to a positive outlook for the remainder of the year. The increase in full-year revenue guidance indicates significant growth potential and positive market sentiment.

6 Nov

4 Investing.com, 5:07 PM
Shoulder Innovations, Inc. (SI) reported a loss in Q1 and announced an acquisition along with a change in its name and stock listing. These developments are part of the company's strategy to enhance its market position and operational capabilities. The acquisition and name change are significant strategic moves that could alter the company's trajectory and investor sentiment.

4 Nov

3 PR Newswire, 4:05 PM
Shoulder Innovations, Inc. (SI) will participate in the Jefferies Global Healthcare Conference, scheduled for June 2023. The event will provide an opportunity for SI to showcase its advancements in shoulder surgery solutions and engage with investors and industry professionals. Details regarding the presentation and participation specifics have not been disclosed. Participation in a prominent healthcare conference can enhance visibility and networking opportunities, potentially influencing investor sentiment and market positioning.

24 Sep

4 , 8:00 AM
Lightstone Ventures has reported significant milestones for its biotech and medtech portfolio companies in 2025, highlighting advancements and achievements that could influence the market landscape. Among these companies is Shoulder Innovations, Inc. (SI), which is noted for its innovative contributions to the medical technology sector. The report emphasizes the strategic growth and potential of these companies, indicating a positive outlook for their future developments. The reported milestones suggest significant advancements that could enhance Shoulder Innovations' market position and investor sentiment.

22 Sep

4 PR NewswirePR NewswirePR Newswire, 6:18 AM
Shoulder Innovations, Inc. has officially launched the InSet™ 70 Humeral Stem, a new product designed to enhance shoulder arthroplasty procedures. This innovative humeral stem is engineered to improve surgical outcomes and patient recovery. The launch marks a significant milestone for the company as it aims to expand its product offerings in the orthopedic market. The launch of the InSet™ 70 Humeral Stem is a major strategic move that could significantly enhance the company's market position and investor sentiment.

1 Sep

4 , 6:34 AM
Shoulder Innovations, Inc. (SI) is highlighted in a recent analysis of two new IPOs, with Morgan Stanley recommending SI as the superior stock to buy. The firm emphasizes SI's innovative approach and potential for growth in the orthopedic market, suggesting strong investor interest and confidence in the company's future performance. Morgan Stanley's endorsement indicates significant investor confidence and potential for market impact.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us